Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib-Reference-Cited by-同舟云学术

Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib

Published:2020-05-26 Issue:13 Volume:63 Page:7186-7210
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Li Yangfeng¹,Zhao Jiong²,Gutgesell Lauren M.²^ORCID,Shen Zhengnan¹,Ratia Kiira¹²³,Dye Katherine¹,Dubrovskyi Oleksii¹,Zhao Huiping²,Huang Fei¹,Tonetti Debra A.²,Thatcher Gregory R. J.¹²^ORCID,Xiong Rui¹²^ORCID

Affiliation:

1. UICentre (Drug Discovery @ UIC), University of Illinois at Chicago, 833 S. Wood Street, Chicago, Illinois 60612, United States

2. Department of Pharmaceutical Sciences, University of Illinois College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street, Chicago, Illinois 60612, United States

3. Research Resources Center, University of Illinois at Chicago, Chicago, Illinois 60612, United States

Funder

National Institutes of Health

Chicago Biomedical Consortium

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00456

Reference83 articles.

1. U.S. Breast Cancer Statistics. https://www.breastcancer.org/symptoms/understand_bc/statistics (accessed Mar 7, 2019).